Trastuzumab-ADC

Trastuzumab-ADC refers to a category of antibody-drug conjugates (ADCs) that utilize the humanized anti-HER2 monoclonal antibody, trastuzumab, as a targeting vehicle to deliver potent cytotoxic agents to HER2-overexpressing malignant cells. This platform includes several FDA-approved therapies, such as ado-trastuzumab emtansine (Kadcyla) and fam-trastuzumab deruxtecan (Enhertu), which have revolutionized the treatment of HER2-positive breast and gastric cancers. In the context of Navrogen's research, "Trastuzumab-ADC" specifically refers to an experimental construct engineered to be refractory to Intercellular Adhesion Molecule 1 (ICAM-1). This modification aims to prevent the ADC from being sequestered by ICAM-1-expressing tissues or tumor-associated factors, thereby potentially improving the therapeutic index and overcoming resistance mechanisms associated with ICAM-1 interference. While the Navrogen variant is primarily utilized as a research tool to investigate the impact of ICAM-1 on ADC efficacy, the broader trastuzumab-ADC platform remains a cornerstone of targeted oncology.

Other names

Trastuzumab antibody-drug conjugate